Spectrum Pharmaceuticals, Inc. In-Licenses Poziotinib, A Novel pan-HER Inhibitor With Clinical Activity In Several Solid Tumors, From Hanmi Pharmaceutical, Co., Ltd

HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced it has entered into a licensing agreement with Hanmi Pharmaceuticals for poziotinib, a drug being investigated for the treatment of cancer.

Help employers find you! Check out all the jobs and post your resume.